BALB/c mice were given cyclophosphamide and challenged with Cryptococcus neofornans. Delayed-type hypersensitivity was transiently depressed, and survival was either unaffected or shortened by cyclophosphamide.
When cyclophosphamide (CY) is administered to laboratory animals, it produces a transient decrease in peripheral blood polymorphonuclear leukocytes (PMN) and lymphocytes. Spleen and lymph node lymphocytes are also depressed. Activity of CY is selectively greater against B-lymphocytes than the thymus-dependent lymphocytes (T-lymphocytes) which effect cell-mediated immunity (8, 9) . Depending on the time of immunization, cell-mediated immunity may be heightened by CY treatment. Finerty and Krehl have also associated CY pretreatment with increased protection in murine malaria (4) . The present studies were undertaken in order to determine whether CY treatment alters delayed-type hypersensitivity (DTH) reactions to extracts of Cryptococcus neofonnans, or affects the course of murine cryptococcosis.-Five-week-old male BALB/c mice were used. Some groups were immunized with cryptococcal extract emulsified in an equal volume of complete Freund adjuvant and challenged 2 weeks later (5). Other groups were immunized on the day CY was given. The test used for DTH reactivity was the mouse ear swelling test. It is analogous to the footpad swelling test, but utilizes the pinna of the ear as a test site (5) . Results were measured in micrometers of antigen-specific ear swelling (SES), and were compared using one-way analysis of variance (ANOVA).
Mice were challenged intraperitoneally with our strain B C. neoformans (5) . The 50% lethal dose within 60 days postchallenge was approximately 600 colony-forming units (CFU), with heavy cryptococcal infestation of spleen, liver, and brain at the time of death. Life Table 2 . Mice infected with cryptococci on day 1 had already developed some SES reactivity to cryptococcin by day 6. Mice which received single doses of CY at 50 or 300 mg/kg had no change in SES reactivity at day 6, but were slightly larger than control mice by day 15. This delay in development' of reactivity was also seen in mice which were not challenged with cryptococci, but instead immunized with cryptococcin.
Finally, CY had either no effect or a deleterious effect on survival of mice with cryptococcosis. Thirty controls received 300 mg of CY per kg but no cryptococci. Two died. Thus, drug toxicity did not account for effects on survival.
In our first study, groups of 10 mice were challenged with 104 C. neoformans and treated on the same day with either saline or 50, 100, or 300 mg of CY per kg. Survival was not altered by CY in any dose. In the next study (Fig. 1) , the challenge dose was increased 106 CFU. At this dose, CY at 300 mg/kg was associated with a significantly increased number of deaths in the first week; thereafter, the survival curve approximated nontreated controls. When mice were pretreated with -CY 10 days before challenge, their mortality was significantly higher than controls or mice treated with CY on the day of challenge (data not shown).
An additional study was conducted in mice challenged with a low dose of 103 CFU (Fig. 2) The present studies included doses of CY which suppressed total leukocyte counts in peripheral blood. Like others, we could not find a dose of CY which selectively affected lymphocytes and not PMN (1, 10) . However, the 50-mg/kg dose, which did not depress leukocyte counts, did delay development of SES reactivity after infection or concurrent immunization. This is consistent with CY acting against a population of T-lymphocytes stimulated by cryptococcal antigens. When DTH was tested 2 weeks after challenge, CY-treated mice had slightly larger reactions than untreated controls. However, the differences were not statistically significant, and do not support a late "exaggerated" T-lymphocyte response as noted for murine malaria (4) .
We also demonstrated no survival benefit conferred by CY, and in several studies CY appeared to increase mortality. These results do not permit conclusions as to the action of CY on a specific immune defense mechanism in cryptococcosis. There are several reasons for this. First, the only effect of CY on survival was noted at the 300-mg/kg dose, which was also associated with marked PMN depression. There is laboratory evidence suggesting that early dissemination of C. neoformans may be prevented by antibody-complement opsonizing phagocytosis by PMN; accordingly, acute leukopenia induced by CY might have permitted overwhelming fungal infection and early death in some mice (3) . Second, in mice receiving CY 10 days before challenge, a maneuver aimed at increasing Tlymphocyte response, there was still early mortality from CY treatment (6) . However, one cannot attribute this effect to low blood PMN, since PMN recovery was occurring by 10 days after CY. Finally, in mice preimmunized with cryptococcin and then given a low cryptococcal challenge, CY treatment did not affect mortality of controls but shortened the survival of immunized mice to the same range as controls. Thus, any effects of CY on host defense were negative.
CY treatment has produced a broad range of effects in other infectious diseases. In histoplasmosis, an infection with clear dependence ofhost defense cell-mediated immunity, CY has adverse consequences on survival (2) . In others, such as listeriosis or mouse malaria, CY appears beneficial in increasing host resistance (4, 7) . These different results may be better understood after we learn whether T-lymphocytes responsible for host defenses in infections may include multiple populations with different susceptibilities to CY.
